{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-033032","form_type":"8-K","ticker":"PHGE","cik":"0001739174","company_name":"BiomX Inc.","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.833961+00:00","generated_at":"2026-06-03T22:57:47.016599+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"BiomX appoints Susan Blum to board as Class II director and audit committee chair; amends bylaws","bullets":["Board size increased to eight; Susan Blum appointed as Class II director with term expiring at 2025 annual meeting.","Blum named chair of audit committee and designated audit committee financial expert.","Blum is CFO of Melinta Therapeutics; previously VP Finance & CAO at Melinta, controller at Textura, and director at Orbitz.","Bylaws amended to eliminate requirement that board and committees be comprised of an odd number of directors.","Indemnification agreement entered into with Blum; terms consistent with other directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-033032","json":"https://secwatch.observer/filing/0001213900-24-033032.json","markdown":"https://secwatch.observer/filing/0001213900-24-033032.md","text":"https://secwatch.observer/filing/0001213900-24-033032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739174/000121390024033032/0001213900-24-033032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739174/000121390024033032/ea0203936-8k_biomxinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:57:47.016599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0124aa1363","claim":"Susan Blum was appointed as Class II Director at BiomX Inc..","evidence_excerpt":"increased the size of the Board to eight members and appointed Susan Blum to serve as a Class II Director of the Company, with a term expiring at the Company’s annual meeting of stockholders in 2025, in order to fill the resulting vacancy on the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390024033032/0001213900-24-033032-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"640949e559b08ca22b93e6a7b66c3f8d8d5800d9","claim":"BiomX Inc.: Eliminated requirements that the Board and its committees be comprised of an odd number of directors by amending Sections 1, 2, and 14 of Article II of the Amended and Restated Bylaws (effective 2024-04-11).","evidence_excerpt":"On April 11, 2024, the Board approved amendments to the Company’s Amended and Restated Bylaws (as so amended, the “Amended Bylaws”), effective as of such date, to eliminate the requirements that the Board and its committees be comprised of an odd number of directors. The Amended Bylaws amend Sections 1, 2 and 14 of Article II of the Amended and Restated Bylaws to delete such requirements.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390024033032/0001213900-24-033032-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-04-11"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}